Stockreport

First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Two doses of rilzabrutinib, 800 mg daily and 1200 mg daily, were studied. The data showed that treatment with oral rilzabrutinib at both high and low doses led to a n [Read more]